{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:48:40Z","timestamp":1792586920860,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Dyslipidemia Foundation, Natick, MA USA","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01308-9","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T08:30:32Z","timestamp":1749457832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review"],"prefix":"10.1007","volume":"27","author":[{"given":"Ernst J.","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela F.","family":"Asztalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Vaisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Diffenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bryan","family":"Brewer Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline O.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"1308_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI103182","volume":"34","author":"RJ Havel","year":"1955","unstructured":"Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345\u201353.","journal-title":"J Clin Invest"},{"key":"1308_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/ajcn\/75.2.191","volume":"75","author":"EJ Schaefer","year":"2002","unstructured":"Schaefer EJ. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr. 2002;75:191\u2013212.","journal-title":"Am J Clin Nutr"},{"key":"1308_CR3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1373\/clinchem.2019.304600","volume":"65","author":"H Ikezaki","year":"2019","unstructured":"Ikezaki H, Fisher VA, Lim E, Ai M, Liu CT, Cupples LA, Nakajima K, Asztalos BF, Furusyo N, Schaefer EJ. Direct versus calculated LDL cholesterol and C-reactive protein in cardiovascular disease risk assessment in the Framingham offspring study. Clin Chem. 2019;65:1102\u201314.","journal-title":"Clin Chem"},{"key":"1308_CR4","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1194\/jlr.M073882","volume":"58","author":"N Thongtang","year":"2017","unstructured":"Thongtang N, Diffenderfer MR, Ooi EMM, Barrett PHR, Turner SM, Le NA, Brown WV, Schaefer EJ. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of Rosuvastatin. J Lipid Res. 2017;58:1315\u201324.","journal-title":"J Lipid Res"},{"key":"1308_CR5","doi-asserted-by":"publisher","first-page":"e019140","DOI":"10.1161\/JAHA.120.019140","volume":"10","author":"H Ikezaki","year":"2021","unstructured":"Ikezaki H, Lim E, Cupples LA, Liu CT, Asztalos BF, Schaefer EJ. Small dense low-density lipoprotein cholesterol is the most atherogenic lipoprotein parameter in the prospective Framingham offspring study. J Am Heart Assoc. 2021;10:e019140.","journal-title":"J Am Heart Assoc"},{"key":"1308_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2023.01.015","volume":"367","author":"EJ Schaefer","year":"2023","unstructured":"Schaefer EJ, Ikezaki H, Diffenderfer MR, Lim E, Liu CT, Hoogeveen RC, Guan W, Tsai MY, Ballantyne CM. Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African americans: the pooling project. Atherosclerosis. 2023;367:15\u201323.","journal-title":"Atherosclerosis"},{"key":"1308_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0022-2275(20)42943-8","volume":"11","author":"M Burstein","year":"1970","unstructured":"Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583\u201395.","journal-title":"J Lipid Res"},{"key":"1308_CR8","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0022-2275(20)38059-7","volume":"23","author":"LI Gidez","year":"1982","unstructured":"Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982;23:1206\u201323.","journal-title":"J Lipid Res"},{"key":"1308_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcla.1031","volume":"15","author":"M Okada","year":"2001","unstructured":"Okada M, Matsui H, Ito Y, Fujiwara A. Direct measurement of HDL cholesterol: method eliminating Apolipoprotein E-rich particles. J Clin Lab Anal. 2001;15:223\u20139.","journal-title":"J Clin Lab Anal"},{"key":"1308_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cca.2014.10.039","volume":"439","author":"M Nakamura","year":"2015","unstructured":"Nakamura M, Yokoyama S, Kayamori Y, Iso H, Kitamura A, Okamura T, Kiyama M, Noda H, Nishimura K, Nakai M, Koyama I, Dasti M, Vesper HW, Teramoto T, Miyamoto Y. HDL cholesterol performance using an ultracentrifugation reference measurement procedure and the designated comparison method. Clin Chim Acta. 2015;439:185\u201390.","journal-title":"Clin Chim Acta"},{"key":"1308_CR11","doi-asserted-by":"crossref","unstructured":"Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha MJ, Carson AP, Chang AR, Ciemins E, Go AS, Gutierrez OM, Hwang SJ, Jassal SK, Kovesdy CP, Lloyd-Jones DM, Shlipak MG, Palaniappan LP, Sperling L, Virani SS, Tuttle K, Neeland IJ, Chow SL, Rangaswami J, Pencina MJ, Ndumele CE, Coresh J, Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American heart association\u2019s PREVENT equations. Circulation. 2024;149:430\u201349.","DOI":"10.1161\/CIRCULATIONAHA.123.067626"},{"key":"1308_CR12","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, Palaniappan LP, Sperling LS, Virani SS, Ho JE, Neeland IJ, Tuttle KR, Rajgopal Singh R, Elkind MSV, Lloyd-Jones DM, American Heart Association. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American heart association. Circulation. 2023;148:1982\u20132004.","journal-title":"Circulation"},{"key":"1308_CR13","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J, 2018 AHA\/ACC\/AACVPR\/AAPA. The management of blood cholesterol: A report of the American college of cardiology\/american heart association task force on clinical practice guidelines. Circulation. 2019;139:e1082\u2013143. \/ABC \/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on.","DOI":"10.1161\/CIR.0000000000000624"},{"key":"1308_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jama.297.6.611","volume":"297","author":"PM Ridker","year":"2007","unstructured":"Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297:611\u20139.","journal-title":"JAMA"},{"key":"1308_CR15","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","volume":"118","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation. 2008;118:2243\u201351.","journal-title":"Circulation"},{"key":"1308_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1172\/JCI26206","volume":"117","author":"T Vaisar","year":"2007","unstructured":"Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW. Shotgun proteomics implicates protease Inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746\u201356.","journal-title":"J Clin Invest"},{"key":"1308_CR17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0022-2275(20)38087-1","volume":"23","author":"EJ Schaefer","year":"1982","unstructured":"Schaefer EJ, Zech LA, Jenkins LL, Bronzert TJ, Rubalcaba EA, Lindgren FT, Aamodt RL, Brewer HB Jr. Human Apolipoprotein A-I and A-II metabolism. J Lipid Res. 1982;23:850\u201362.","journal-title":"J Lipid Res"},{"key":"1308_CR18","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1161\/CIRCULATIONAHA.116.025678","volume":"135","author":"AV Khera","year":"2017","unstructured":"Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, Rader DJ, Mora S. Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: an analysis from the JUPITER trial (Justification for the use of Statins in prevention: an intervention trial evaluating Rosuvastatin). Circulation. 2017;135:2494\u2013504.","journal-title":"Circulation"},{"key":"1308_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RI, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127\u201335.","journal-title":"N Engl J Med"},{"key":"1308_CR20","doi-asserted-by":"crossref","unstructured":"Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383\u201393.","DOI":"10.1056\/NEJMoa1409065"},{"key":"1308_CR21","doi-asserted-by":"crossref","unstructured":"Niisuke K, Kuklenyik Z, Horvath KV, Gardner MS, Toth CA, Asztalos BF. Composition-function analysis of HDL subpopulations: influence of lipid composition on particle functionality. J Lipid Res. 2020;61:306-15.","DOI":"10.1194\/jlr.RA119000258"},{"key":"1308_CR22","doi-asserted-by":"publisher","first-page":"118565","DOI":"10.1016\/j.atherosclerosis.2024.118565","volume":"397","author":"T Vaisar","year":"2024","unstructured":"Vaisar T, Babenko I, Horvath KV, Niisuke K, Asztalos BF. Relationships between HDL subpopulation proteome and HDL function in overweight\/obese people with and without coronary heart disease. Atherosclerosis. 2024;397:118565.","journal-title":"Atherosclerosis"},{"key":"1308_CR23","unstructured":"Geller AS, Polisecki EY, Diffenderfer MR, Asztalos BF, Karathanasis SK, Hegele RA, Schaefer EJ. Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. J Lipid Res."},{"key":"1308_CR24","doi-asserted-by":"crossref","unstructured":"Asztalos BF, Russo G, He L, Diffenderfer MR. Body mass index and cardiovascular risk markers: a large population analysis. Nutrients. 2025;17:740.","DOI":"10.3390\/nu17050740"},{"key":"1308_CR25","doi-asserted-by":"crossref","unstructured":"Asztalos BF, Hauser TH, Goldfine AB, Welty FK, Horvath KV, Schaefer EJ. The role of HDL- and non-HDL-related parameters in cell-cholesterol efflux capacity. Atherosclerosis. 2022;345:1\u20136.","DOI":"10.1016\/j.atherosclerosis.2022.02.012"},{"key":"1308_CR26","doi-asserted-by":"crossref","unstructured":"Stock EO, Asztalos BF, Miller JM, He L, Creasy KT, Schwemberger R, Quinn A, Pullinger CR, Malloy MJ, Diffenderfer MR, Kane JP. High-density lipoprotein particles, inflammation, and coronary heart disease risk. Nutrients. 2025;17:1182.","DOI":"10.3390\/nu17071182"},{"key":"1308_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/MOL.0b013e328353eef1","volume":"23","author":"JP Kane","year":"2012","unstructured":"Kane JP, Malloy MJ. Prebeta-1 HDL and coronary heart disease. Curr Opin Lipidol. 2012;23:367\u201371.","journal-title":"Curr Opin Lipidol"},{"key":"1308_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0005-2760(93)90253-6","volume":"1169","author":"BF Asztalos","year":"1993","unstructured":"Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new Apo A-I-containing subpopulations. Biochim Biophys Acta. 1993;1169:291\u2013300.","journal-title":"Biochim Biophys Acta"},{"key":"1308_CR29","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1194\/jlr.M500187-JLR200","volume":"46","author":"BF Asztalos","year":"2005","unstructured":"Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1 and SR-B1-mediated cholesterol efflux. J Lipid Res. 2005;46:2246\u201353.","journal-title":"J Lipid Res"},{"key":"1308_CR30","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1161\/01.ATV.20.12.2670","volume":"20","author":"BF Asztalos","year":"2000","unstructured":"Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2670\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1308_CR31","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1161\/01.ATV.0000066133.32063.BB","volume":"23","author":"BF Asztalos","year":"2003","unstructured":"Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:847\u201352.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1308_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/ATVBAHA.107.157123","volume":"28","author":"S Lamon-Fava","year":"2008","unstructured":"Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath KV, Cupples LA, White C, Demissie S, Schaefer EJ, Asztalos BF. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2008;28:575\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1308_CR33","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1161\/01.ATV.0000146325.93749.a8","volume":"24","author":"BF Asztalos","year":"2004","unstructured":"Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham offspring study. Arterioscler Thromb Vasc Biol. 2004;24:2181\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1308_CR34","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1161\/01.ATV.0000183727.90611.4f","volume":"25","author":"BF Asztalos","year":"2005","unstructured":"Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Biol. 2005;25:2185\u201391.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1308_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.metabol.2007.08.009","volume":"57","author":"BF Asztalos","year":"2008","unstructured":"Asztalos BF, Collins D, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the veterans affairs High-Density lipoprotein intervention trial. Metabolism. 2008;57:77\u201383.","journal-title":"Metabolism"},{"key":"1308_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.amjcard.2011.03.054","volume":"108","author":"LT Guey","year":"2011","unstructured":"Guey LT, Pullinger CR, Ishida BY, O\u2019Connor PM, Zellner C, Francone OL, Laramie JM, Naya-Vigne JM, Siradze KA, Deedwania P, Redberg RF, Frost PH, Seymour AB, Kane JP, Malloy MJ. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol. 2011;108:360\u20136.","journal-title":"Am J Cardiol"},{"key":"1308_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jacl.2017.11.001","volume":"12","author":"EO Stock","year":"2018","unstructured":"Stock EO, Ferrara CT, O\u2019Connor PM, Naya-Vigne JM, Frost PH, Malloy MJ, Kane JP, Pullinger CR. Levels of prebeta-1 high-density lipoprotein are elevated in 3 phenotypes of dyslipidemia. J Clin Lipidol. 2018;12:99\u2013109.","journal-title":"J Clin Lipidol"},{"key":"1308_CR38","doi-asserted-by":"publisher","first-page":"e018381","DOI":"10.1161\/JAHA.120.018381","volume":"10","author":"CR Pullinger","year":"2021","unstructured":"Pullinger CR, O\u2019Connor PM, Naya-Vigne JM, Kunitake ST, Movsesyan I, Frost PH, Malloy MJ, Kane JP. Levels of prebeta-1 high-density lipoprotein are a strong independent positive risk factor for coronary heart disease and myocardial infarction: a meta-analysis. J Am Heart Assoc. 2021;10:e018381.","journal-title":"J Am Heart Assoc"},{"key":"1308_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pcad.2016.08.006","volume":"59","author":"EJ Schaefer","year":"2016","unstructured":"Schaefer EJ, Anthanont P, Diffenderfer MR, Polisecki E, Asztalos BF. Diagnosis and treatment of high-density lipoprotein deficiency. Prog Cardiovasc Dis. 2016;59:97\u2013106.","journal-title":"Prog Cardiovasc Dis"},{"key":"1308_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/01.ATV.2.1.16","volume":"2","author":"EJ Schaefer","year":"1982","unstructured":"Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr. Plasma Apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis. 1982;2:16\u201326.","journal-title":"Arteriosclerosis"},{"key":"1308_CR41","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S0022-2275(20)34282-6","volume":"26","author":"EJ Schaefer","year":"1985","unstructured":"Schaefer EJ, Ordovas JM, Law SW, Ghiselli G, Kashyap ML, Srivastava LS, Heaton WH, Albers JJ, Connor WE, Lindgren FT, Lemeshev Y, Segrest JP, Brewer HB Jr. Familial Apolipoprotein A-I and C-III deficiency, variant II. J Lipid Res. 1985;26:1089\u2013101.","journal-title":"J Lipid Res"},{"key":"1308_CR42","doi-asserted-by":"publisher","first-page":"16339","DOI":"10.1016\/S0021-9258(19)84708-7","volume":"264","author":"JM Ordovas","year":"1989","unstructured":"Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ. Familial Apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem. 1989;264:16339\u201342.","journal-title":"J Biol Chem"},{"key":"1308_CR43","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2014.05.935","volume":"235","author":"P Anthanont","year":"2014","unstructured":"Anthanont P, Polisecki E, Asztalos BF, Diffenderfer MR, Barrett PH, Millar JS, Billheimer J, Cuchel M, Rader DJ, Schaefer EJ. A novel apoA-I Truncation (ApoA-IMytilene) associated with decreased apoA-I production. Atherosclerosis. 2014;235:470\u20136.","journal-title":"Atherosclerosis"},{"key":"1308_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1194\/jlr.M700362-JLR200","volume":"49","author":"RD Santos","year":"2008","unstructured":"Santos RD, Schaefer EJ, Asztalos BF, Polisecki E, Wang J, Hegele RA, Martinez LR, Miname MH, Rochitte CE, Da Luz PL, Maranh\u00e3o RC. Characterization of high density lipoprotein particles in Familial Apolipoprotein A-I deficiency. J Lipid Res. 2008;49:349\u201357.","journal-title":"J Lipid Res"},{"key":"1308_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1172\/JCI104907","volume":"43","author":"DS Fredrickson","year":"1964","unstructured":"Fredrickson DS. The inheritance of high-density lipoprotein deficiency (Tangier Disease). J Clin Invest. 1964;43:228\u201336.","journal-title":"J Clin Invest"},{"key":"1308_CR46","first-page":"101","volume":"78","author":"VJ Ferrans","year":"1975","unstructured":"Ferrans VJ, Fredrickson DS. The pathology of Tangier disease. A light and electron microscopic study. Am J Pathol. 1975;78:101\u201358.","journal-title":"Am J Pathol"},{"key":"1308_CR47","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM197810262991701","volume":"299","author":"EJ Schaefer","year":"1978","unstructured":"Schaefer EJ, Blum CB, Levy RI, Jenkins LL, Alaupovic P, Foster DM, Brewer HB Jr. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N Engl J Med. 1978;299:905\u201310.","journal-title":"N Engl J Med"},{"key":"1308_CR48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.7326\/0003-4819-93-2-261","volume":"93","author":"EJ Schaefer","year":"1980","unstructured":"Schaefer EJ, Zech LA, Schwartz DE, Brewer HB Jr. Coronary heart disease prevalence and other clinical features in Familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med. 1980;93:261\u20136.","journal-title":"Ann Intern Med"},{"key":"1308_CR49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/11921","volume":"22","author":"S Rust","year":"1999","unstructured":"Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Den\u00e8fle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352\u20135.","journal-title":"Nat Genet"},{"key":"1308_CR50","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0022-2275(20)34482-5","volume":"41","author":"ME Brousseau","year":"2000","unstructured":"Brousseau ME, Schaefer EJ, Dupuis J, Eustace B, Van Eerdewegh P, Goldkamp AL, Thurston LM, FitzGerald MG, Yasek-McKenna D, O\u2019Neill G, Eberhart GP, Weiffenbach B, Ordovas JM, Freeman MW, Brown RH Jr, Gu JZ. Novel mutations in the gene encoding ATP-binding cassette 1 in four Tangier disease kindreds. J Lipid Res. 2000;41:433\u201341.","journal-title":"J Lipid Res"},{"key":"1308_CR51","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S0022-2275(20)32019-8","volume":"41","author":"ME Brousseau","year":"2000","unstructured":"Brousseau ME, Eberhart GP, Dupuis J, Asztalos BF, Goldkamp AL, Schaefer EJ, Freeman MW. Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J Lipid Res. 2000;41:1125\u201335.","journal-title":"J Lipid Res"},{"key":"1308_CR52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0021-9150(00)00643-2","volume":"156","author":"BF Asztalos","year":"2001","unstructured":"Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ. Subpopulations of high-density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis. 2001;156:217\u201325.","journal-title":"Atherosclerosis"},{"key":"1308_CR53","doi-asserted-by":"crossref","unstructured":"Norum KR, Remaley AT, Miettinen HE, Str\u00f8m EH, Balbo BEP, Sampaio CATL, Wiig I, Kuivenhoven JA, Calabresi L, Tesmer JJ, Zhou M, Ng DS, Skeie B, Karathanasis SK, Manthei KA, Retterst\u00f8l K. Lecithin:cholesterol acyltransferase: symposium on 50 years of biomedical research from its discovery to latest findings. J Lipid Res. 2020;61:1142-9.","DOI":"10.1194\/jlr.S120000720"},{"key":"1308_CR54","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1194\/jlr.M600403-JLR200","volume":"48","author":"BF Asztalos","year":"2007","unstructured":"Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G, Calabresi L. Role of LCAT in HDL remodeling: investigation of LCAT deficiency States. J Lipid Res. 2007;48:592\u20139.","journal-title":"J Lipid Res"},{"key":"1308_CR55","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1172\/JCI115028","volume":"87","author":"EA Brinton","year":"1991","unstructured":"Brinton EA, Eisenberg S, Breslow JL. Increased Apo A-I and Apo A-II fractional catabolic rate in patients with low high-density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 1991;87:536\u201344.","journal-title":"J Clin Invest"},{"key":"1308_CR56","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1194\/jlr.M300198-JLR200","volume":"45","author":"BF Asztalos","year":"2004","unstructured":"Asztalos BF, Horvath KV, Kajinami K, Nartsupha C, Cox CE, Batista M, Schaefer EJ, Inazu A, Mabuchi H. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res. 2004;45:448\u201355.","journal-title":"J Lipid Res"},{"key":"1308_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2016.08.014","volume":"253","author":"M Tani","year":"2016","unstructured":"Tani M, Horvath KV, Lamarche B, Couture P, Burnett JR, Schaefer EJ, Asztalos BF. High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency. Atherosclerosis. 2016;253:7\u201314.","journal-title":"Atherosclerosis"},{"key":"1308_CR58","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11745-008-3169-2","volume":"43","author":"JH Graversen","year":"2008","unstructured":"Graversen JH, Castro G, Kandoussi A, Nielsen H, Christensen EI, Norden A, Moestrup SK. A pivotal role of the human kidney in catabolism of HDL protein components Apolipoprotein A-I and A-IV but not of A-II. Lipids. 2008;43:467\u201370.","journal-title":"Lipids"},{"key":"1308_CR59","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"P Zanoni","year":"2016","unstructured":"Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, DerOhannessian S, Kontush A, Surendran P, Saleheen D, Trompet S, Jukema JW, De Craen A, Deloukas P, Sattar N, Ford I, Packard C, Majumder Aa, Alam DS, Di Angelantonio E, Abecasis G, Chowdhury R, Erdmann J, Nordestgaard BG, Nielsen SF, Tybj\u00e6rg-Hansen A, Schmidt RF, Kuulasmaa K, Liu DJ, Perola M, Blankenberg S, Salomaa V, M\u00e4nnist\u00f6 S, Amouyel P, Arveiler D, Ferrieres J, M\u00fcller-Nurasyid M, Ferrario M, Kee F, Willer CJ, Samani N, Schunkert H, Butterworth AS, Howson JM, Peloso GM, Stitziel NO, Danesh J, Kathiresan S, Rader DJ. CHD exome\u2009+ consortium; cardiogram exome consortium; global lipids genetics consortium. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 2016;351:1166\u201371.","journal-title":"Science"},{"key":"1308_CR60","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1194\/jlr.M200055-JLR200","volume":"43","author":"JS Cohn","year":"2002","unstructured":"Cohn JS, Tremblay M, Batal R, Jacques H, Veilleux L, Rodriguez C, Bernier L, Mamer O, Davignon J. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 2002;43:1680\u20137.","journal-title":"J Lipid Res"},{"key":"1308_CR61","doi-asserted-by":"crossref","unstructured":"Batal R, Tremblay M, Barrett PH, Jacques H, Fredenrich A, Mamer O, Davignon J, Cohn JS. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res., Sacks FM, Aikawa M, Singh SA. Understanding HDL metabolism and biology through in vivo tracer kinetics. Arterioscler Thromb Vasc Biol. 2024;44:76\u201388.","DOI":"10.1161\/ATVBAHA.123.319742"},{"key":"1308_CR62","doi-asserted-by":"crossref","unstructured":"Brewer HB Jr, Schaefer EJ, Foldyna B, Ghoshhajra BB. High-density lipoprotein infusion therapy: A review. J Clin Lipidol. 2024;18:e374\u201383.","DOI":"10.1016\/j.jacl.2024.01.009"},{"key":"1308_CR64","doi-asserted-by":"crossref","unstructured":"Gibson CM, Duffy D, Bahit MC, Chi G, White H, Korjian S, Alexander JH, Lincoff AM, Heise M, Kingwell BA, Nicolau JC, Lopes RD, Cornel JH, Lewis BS, Vinereanu D, Goodman SG, Bode C, Steg PG, Libby P, Sacks FM, Bainey KR, Ridker PM, Mahaffey KW, Aylward P, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA; AEGIS-II Committees and Investigators. Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial. Eur Heart J. 2024;45:5023\u201338.","DOI":"10.1093\/eurheartj\/ehae614"},{"key":"1308_CR65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11883-025-01281-3","volume":"27","author":"NSR Lan","year":"2025","unstructured":"Lan NSR, Watts GF. Quo vadis after AEGIS: new opportunities for therapies targeted at reverse cholesterol transport? Curr Atheroscler Rep. 2025;27:35.","journal-title":"Curr Atheroscler Rep"},{"key":"1308_CR66","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/MOL.0b013e3283612454","volume":"24","author":"EJ Schaefer","year":"2013","unstructured":"Schaefer EJ. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in Lowering coronary heart disease risk? Curr Opin Lipidol. 2013;24:259\u201364.","journal-title":"Curr Opin Lipidol"},{"key":"1308_CR67","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"PM Ridker","year":"2009","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER trial study group. Lancet. 2009;373:1175\u201382.","journal-title":"Lancet"},{"key":"1308_CR68","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between Lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289\u201397.","journal-title":"JAMA"},{"key":"1308_CR69","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.amjcard.2007.08.035","volume":"101","author":"M Ai","year":"2008","unstructured":"Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ. Effects of maximal doses of Atorvastatin versus Rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol. 2008;101:315\u20138.","journal-title":"Am J Cardiol"},{"key":"1308_CR70","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.amjcard.2006.09.117","volume":"99","author":"BF Asztalos","year":"2007","unstructured":"Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ. Comparison of the effects of high doses of Rosuvastatin versus Atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol. 2007;99:681\u20135.","journal-title":"Am J Cardiol"},{"key":"1308_CR71","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1194\/jlr.P900015-JLR200","volume":"51","author":"BF Asztalos","year":"2010","unstructured":"Asztalos BF, Swarbrick MM, Schaefer EJ, Dallal GE, Horvath KV, Ai M, Stanhope KL, Austrheim-Smith I, Wolfe BM, Ali M, Havel PJ. Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res. 2010;51:2405\u201312.","journal-title":"J Lipid Res"},{"key":"1308_CR72","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jacl.2018.12.001","volume":"13","author":"M Dansinger","year":"2019","unstructured":"Dansinger M, Williams PT, Superko HR, Asztalos BF, Schaefer EJ. Effects of weight change on HDL-cholesterol and its subfractions in over 28,000 men and women. J Clin Lipidol. 2019;13:308\u201316.","journal-title":"J Clin Lipidol"},{"key":"1308_CR73","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM \u2022Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torn\u00f8e CW, Ryan DH. SELECT trial investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01308-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01308-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01308-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:02:49Z","timestamp":1749499369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01308-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01308-9","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"29 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is a review article so there are no concerns with regard to these issues.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Subjects, Animal Studies, and Informed Consent"}},{"value":"E.J.S. and M.R.D. are employees of Boston Heart Diagnostics, Framingham, MA, USA.None of the other authors has any competing financial and\/or non-financial interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"62"}}